News & Events

Latest Blog Posts & Events

One Year in Cancer Research and Much to Celebrate
NCI Director Dr. Kimryn Rathmell reviews some of the most noteworthy cancer research findings from 2024.
Cetuximab Remains a Treatment Option for Some Head and Neck Cancers
Cetuximab outperformed durvalumab in trial participants who could not receive cisplatin.
Improving Symptom Control in Young Cancer Patients
Helping kids and teens with cancer report how they feel helps control symptoms, reduces side effects.

Latest Press Releases

In five cancer types, prevention and screening have been major contributors to saving lives
- December 5, 2024
Over the past 45 years, the majority of deaths averted from breast, cervical, colorectal, lung, and prostate cancer were due to prevention and screening, rather than treatment advances, NCI researchers have found.
Researchers uncover new role of mutant RAS proteins in some of the deadliest cancers
- November 11, 2024
A new study led by NCI researchers shows that mutant RAS proteins help release a nuclear protein from a complex transported from the nucleus to the cytoplasm, kicking off a series of events that lead to the breakdown of a tumor suppressor protein.
NIH-funded scientists uncover clues to precancer and tumor biology
- October 30, 2024
New studies released by NCI’s Human Tumor Atlas Network explore the role of the tumor microenvironment and the immune system in promoting the spread of cancer and its resistance to treatment. The studies appear across several Nature journals.
NIH clinical trial will test precision medicine treatments for myeloid cancers
- October 23, 2024
NCI has launched myeloMATCH, a precision medicine treatment trial that will test treatment combinations targeting specific genetic changes in people with acute myeloid leukemia and myelodysplastic syndromes.
New cancer diagnoses did not rebound as expected following pandemic
- September 24, 2024
While new cancer diagnoses largely returned to pre-pandemic levels in 2021, they don’t account for the missed diagnoses in early 2020 that resulted from disruptions in cancer screening and other medical care.